BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37446260)

  • 21. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
    Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
    Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime.
    Pradip D; Jennifer A; Nandini D
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer.
    Kawasaki K; Noma K; Kato T; Ohara T; Tanabe S; Takeda Y; Matsumoto H; Nishimura S; Kunitomo T; Akai M; Kobayashi T; Nishiwaki N; Kashima H; Maeda N; Kikuchi S; Tazawa H; Shirakawa Y; Fujiwara T
    Cancer Immunol Immunother; 2023 Nov; 72(11):3787-3802. PubMed ID: 37668710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 and PD-L2 expression in colorectal cancer.
    Zeynep O; Funda C; Evrim Y; Deniz A; Bülent Y; Fatih YN
    Indian J Pathol Microbiol; 2023; 66(1):31-37. PubMed ID: 36656207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer-associated Fibroblast-derived Extracellular Vesicles Mediate Immune Escape of Bladder Cancer via PD-L1/PD-1 Expression.
    Feng R; Li Z; Ge G; Wang C; Jia Y; Ouyang J
    Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1410-1420. PubMed ID: 36852791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
    Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
    Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
    Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
    López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
    J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
    Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
    Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.
    Suszczyk D; Skiba W; Zardzewiały W; Pawłowska A; Włodarczyk K; Polak G; Tarkowski R; Wertel I
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
    Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K
    Front Oncol; 2019; 9():883. PubMed ID: 31572677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
    Taube JM; Klein A; Brahmer JR; Xu H; Pan X; Kim JH; Chen L; Pardoll DM; Topalian SL; Anders RA
    Clin Cancer Res; 2014 Oct; 20(19):5064-74. PubMed ID: 24714771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent High PD-L1 Expression and CD8
    Shimoda Y; Shibaki R; Yoshida T; Murakami S; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y; Motoi N
    Clin Lung Cancer; 2022 Sep; 23(6):477-486. PubMed ID: 35644780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer.
    Qin A; Lima F; Bell S; Kalemkerian GP; Schneider BJ; Ramnath N; Lew M; Krishnan S; Mohammed S; Rao A; Frankel TL
    Sci Rep; 2022 May; 12(1):9054. PubMed ID: 35641540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
    Pinto N; Park JR; Murphy E; Yearley J; McClanahan T; Annamalai L; Hawkins DS; Rudzinski ER
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28488345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.